

Multiple Sclerosis (MS) Drugs-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/MF21740E800MEN.html>

Date: February 2018

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: MF21740E800MEN

Abstracts

Report Summary

Multiple Sclerosis (MS) Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Multiple Sclerosis (MS) Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Multiple Sclerosis (MS) Drugs 2013-2017, and development forecast 2018-2023

Main market players of Multiple Sclerosis (MS) Drugs in United States, with company and product introduction, position in the Multiple Sclerosis (MS) Drugs market
Market status and development trend of Multiple Sclerosis (MS) Drugs by types and applications

Cost and profit status of Multiple Sclerosis (MS) Drugs, and marketing status

Market growth drivers and challenges

The report segments the United States Multiple Sclerosis (MS) Drugs market as:

United States Multiple Sclerosis (MS) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest
The West
The South
Southwest

United States Multiple Sclerosis (MS) Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Finategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others

United States Multiple Sclerosis (MS) Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

RRMS
SPMS
PPMS
PRMS

United States Multiple Sclerosis (MS) Drugs Market: Players Segment Analysis
(Company and Product introduction, Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price and Gross Margin):

Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope

Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF MULTIPLE SCLEROSIS (MS) DRUGS

- 1.1 Definition of Multiple Sclerosis (MS) Drugs in This Report
- 1.2 Commercial Types of Multiple Sclerosis (MS) Drugs
 - 1.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
 - 1.2.2 Novantrone (Mitoxantrone)
 - 1.2.3 Gilenya (Fingolimod, Fty720)
 - 1.2.4 Aubagio (Teriflunomide)
 - 1.2.5 Tecfidera (Dimethyl Fumarate)
 - 1.2.6 Finategrast (Sb683699, T-0047)
 - 1.2.7 Siponimod (Baf312)
 - 1.2.8 Others
- 1.3 Downstream Application of Multiple Sclerosis (MS) Drugs
 - 1.3.1 RRMS
 - 1.3.2 SPMS
 - 1.3.3 PPMS
 - 1.3.4 PRMS
- 1.4 Development History of Multiple Sclerosis (MS) Drugs
- 1.5 Market Status and Trend of Multiple Sclerosis (MS) Drugs 2013-2023
 - 1.5.1 United States Multiple Sclerosis (MS) Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Multiple Sclerosis (MS) Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Multiple Sclerosis (MS) Drugs in United States 2013-2017
- 2.2 Consumption Market of Multiple Sclerosis (MS) Drugs in United States by Regions
 - 2.2.1 Consumption Volume of Multiple Sclerosis (MS) Drugs in United States by Regions
 - 2.2.2 Revenue of Multiple Sclerosis (MS) Drugs in United States by Regions
- 2.3 Market Analysis of Multiple Sclerosis (MS) Drugs in United States by Regions
 - 2.3.1 Market Analysis of Multiple Sclerosis (MS) Drugs in New England 2013-2017
 - 2.3.2 Market Analysis of Multiple Sclerosis (MS) Drugs in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Multiple Sclerosis (MS) Drugs in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Multiple Sclerosis (MS) Drugs in The West 2013-2017
 - 2.3.5 Market Analysis of Multiple Sclerosis (MS) Drugs in The South 2013-2017
 - 2.3.6 Market Analysis of Multiple Sclerosis (MS) Drugs in Southwest 2013-2017

2.4 Market Development Forecast of Multiple Sclerosis (MS) Drugs in United States 2018-2023

2.4.1 Market Development Forecast of Multiple Sclerosis (MS) Drugs in United States 2018-2023

2.4.2 Market Development Forecast of Multiple Sclerosis (MS) Drugs by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Multiple Sclerosis (MS) Drugs in United States by Types

3.1.2 Revenue of Multiple Sclerosis (MS) Drugs in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Multiple Sclerosis (MS) Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Multiple Sclerosis (MS) Drugs in United States by Downstream Industry

4.2 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry in New England

4.2.2 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry in The Midwest

4.2.4 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry in The West

4.2.5 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry in The South

4.2.6 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry in

Southwest

4.3 Market Forecast of Multiple Sclerosis (MS) Drugs in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

5.1 United States Economy Situation and Trend Overview

5.2 Multiple Sclerosis (MS) Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 MULTIPLE SCLEROSIS (MS) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Multiple Sclerosis (MS) Drugs in United States by Major Players

6.2 Revenue of Multiple Sclerosis (MS) Drugs in United States by Major Players

6.3 Basic Information of Multiple Sclerosis (MS) Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Multiple Sclerosis (MS) Drugs Major Players

6.3.2 Employees and Revenue Level of Multiple Sclerosis (MS) Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 MULTIPLE SCLEROSIS (MS) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Bayer AG

7.1.1 Company profile

7.1.2 Representative Multiple Sclerosis (MS) Drugs Product

7.1.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Bayer AG

7.2 Bayhill Therapeutics

7.2.1 Company profile

7.2.2 Representative Multiple Sclerosis (MS) Drugs Product

7.2.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Bayhill Therapeutics

7.3 Biogen Idec

7.3.1 Company profile

- 7.3.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.3.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
- 7.4 Cinnagen
 - 7.4.1 Company profile
 - 7.4.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.4.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Cinnagen
- 7.5 Daiichi Sankyo
 - 7.5.1 Company profile
 - 7.5.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.5.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo
- 7.6 Eli Lilly
 - 7.6.1 Company profile
 - 7.6.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.6.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.7 Fast Forward Llc
 - 7.7.1 Company profile
 - 7.7.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.7.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Fast Forward Llc
- 7.8 Antisense Therapeutics
 - 7.8.1 Company profile
 - 7.8.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.8.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Antisense Therapeutics
- 7.9 Apitope
 - 7.9.1 Company profile
 - 7.9.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.9.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Apitope
- 7.10 Five Prime Therapeutics
 - 7.10.1 Company profile
 - 7.10.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.10.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Five Prime Therapeutics
- 7.11 Genmab

- 7.11.1 Company profile
- 7.11.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.11.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Genmab
- 7.12 Artielle Immunotherapeutics
 - 7.12.1 Company profile
 - 7.12.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.12.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Artielle Immunotherapeutics
- 7.13 Genzyme
 - 7.13.1 Company profile
 - 7.13.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.13.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Genzyme
- 7.14 Glaxosmithkline
 - 7.14.1 Company profile
 - 7.14.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.14.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Glaxosmithkline
- 7.15 Gw Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.15.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Gw Pharmaceuticals
- 7.16 Innate Immunotherapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

- 8.1 Industry Chain of Multiple Sclerosis (MS) Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

- 9.1 Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
- 9.2 Raw Materials Cost Analysis of Multiple Sclerosis (MS) Drugs
- 9.3 Labor Cost Analysis of Multiple Sclerosis (MS) Drugs

9.4 Manufacturing Expenses Analysis of Multiple Sclerosis (MS) Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Multiple Sclerosis (MS) Drugs-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/MF21740E800MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF21740E800MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970